Olfera harnesses the neuro-olfactory epithelium to develop life-changing treatments for brain diseases. Our platform enables effective delivery of therapeutic modalities to the brain and facilitates the discovery of novel drugs for neurodegenerative conditions. To learn more, please visit https://olferatx.com/

Box (NYSE:BOX) is the Intelligent Content Cloud, a single platform that enables organizations to fuel collaboration, manage the entire content lifecycle, secure critical content, and transform business workflows with enterprise AI. Founded in 2005, Box simplifies work for leading global organizations, including AstraZeneca, JLL, Morgan Stanley, and Nationwide. Box is headquartered in Redwood City, CA, with offices across the United States, Europe, and Asia. For more information, go to https://www.box.org

OCCAM Immune is a non-profit Academic Research Organization emerging from Mount Sinai Hospital that provides immune monitoring services for clinical trials. Its streamlined process, from contracting to data delivery, and its one-stop shop approach—from sample processing to assays and data analysis—bridge academic research excellence with industrial scalability. For more information, go to https://occam-immune.com/

Suntec Medical is a biotech innovator transforming cancer and CNS disease therapies with its MINC technology. MINC can deliver biologics to the brain at 100-1000x higher dosages with high efficacy and safety. Our lead drugs, STM-001 for glioma and STM-003 for Alzheimer’s, are entering Phase I/IIa trials in Q3/2024 and Q2/2025. Our portfolio includes treatments for Parkinson’s and other neural diseases. Discover more about our groundbreaking work at https://suntecmedical.com/

SonoThera is pioneering the future of genetic medicine with our groundbreaking ultrasound-guided, redosable, non-viral gene therapy platform. We offer a revolutionary approach to genetic therapies, enabling precise, non-invasive delivery of diverse genetic payloads—including large and complex formats like DNA and RNA—across virtually any organ in the body. Based in South San Francisco, SonoThera secured $60 million in Series A funding with ARCH as lead in late 2022. As we advance our pipeline of research and pre-clinical programs, we are poised to initiate our first clinical trials in 2025, setting the stage for a new era in genetic medicine. For more information, visit https://sonothera.com/

Envoya Inc. is a pioneering biotechnology company specializing in the development of non-lipid polymer-based nanoparticles for gene delivery. Leveraging cutting-edge research and innovative technology, Envoya has successfully crafted nanoparticles that stand out due to their exceptional safety and efficacy profiles. Envoya Inc. is at the forefront of a transformative wave in gene therapy, offering solutions that promise to overcome some of the most persistent challenges in the field. Their innovative use of FDA-approved, non-lipid polymers to create non-immunogenic nanoparticles with high payload encapsulation and transfection efficacy represents a significant leap forward. With a firm commitment to excellence and innovation, Envoya Inc. is poised to make a substantial impact on the future of medicine, bringing forth new possibilities for personalized and effective gene-based treatments. For more information, visit https://www.envoyabio.com/

Fzata’s vision is to be the world leader in oral biologics. We have captured the “holy grail” of oral biologics with our first-in-class live Bioengineered Probiotic Yeast Medicines (BioPYMTM) Platform. Our mission is to transform patient safety, efficacy & access to biologics with BioPYM. NIH has vetted and validated our platform; designating Fzata as an NIH Seed Company with over $27MM in grants. Fzata is also honored to be a Startup Stadium Finalist at BIO2024.

We are raising a $10M series A to support manufacturing, pipeline activities and G&A. We are also seeking pharma partners for our lead assets and/or a pilot program. For more information, please visit https://www.fzata.com/

Deep 6 AI is the leading precision research platform, enabling healthcare organizations and life sciences companies to gain visibility into study design, accelerate recruitment, and generate real-world evidence with unprecedented speed and precision. Its AI-powered software mines structured and unstructured electronic medical record data to precisely match patients to clinical trials in real time across its ecosystem of 25+ health systems. For more information, go to https://deep6.ai/

German CDMO operating in biotech and pharmaceuticals fields with core expertise in nanotechnologies & particle engineering. Our R&D labs and cGMP-manufacturing site provide end to end solutions from concept to clinical batch manufacturing including development, transfer and GMP production of nano- and microparticle formulations. We also provide Quality Control, Batch release and Stability studies. To learn more, please visit https://mybiotech.de/

Lipoid is a major international supplier of phospholipids for usage as pharmaceutical excipients. We have a strong focus on quality. Our products are GMP, many have Drug Master Files, and many are utilized in commercial drug products. Lipoid is also known for its expertise in bulk production. This allows us to keep prices affordable and allows you to use identical material in both your first small scale preclinical batch and your future commercial batches. Phospholipids are most known for their use in parenteral applications, such as injectable emulsions and liposomes. They are also excellent excipients in oral, pulmonary, and topical applications, among others. In these applications they improve the bioavailability, solubility, and permeability. For more information, visit https://lipoid.com/en/

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix has created three nanophysics-based technology platforms with multiple product applications: 1) nano-radioenhancers to help millions of patients receiving radiotherapy; 2) nanoprimers to overcome challenges with liver clearance and redefine the way drugs can be designed bioavailability; and 3) nanoparticles for disorders of the central and peripheral nervous system. For more information, visit www.nanobiotix.com

Nutcracker Therapeutics is an RNA therapeutics company that has combined advanced engineering with high-precision biosynthesis to deploy a platform that encompasses the design, delivery and manufacturing of RNA medicines. The company has initiated therapeutic programs with the support of clinical investigators at leading institutions. Its platform has the potential to reduce costs and cycle times with advantages in speed and capacity scaling over other manufacturing approaches. To learn more, please visit https://www.nutcrackerx.com/